Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Alfa1 Antitrypsin

Phase 2Small molecule

MMedical University Innsbruck

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol-Associated HepatitisRecruiting

Alcohol-Associated HepatitisPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Alcohol-Associated Hepatitis

NCT06582329

Clinical

Trials by Indication[1]

Alcohol-Associated Hepatitis1 trial

Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis - A Prospective Pilot Study

Recruiting·MMedical University Innsbruck·Phase 2·NCT06582329·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alfa1 Antitrypsin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alfa1 Antitrypsin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alfa1 Antitrypsin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University Innsbruck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedical University Innsbruck

Related News